MARKET

ARCT

ARCT

Arcturus
NASDAQ

Real-time Quotes | Nasdaq Last Sale

50.46
+3.57
+7.61%
After Hours: 52.64 +2.18 +4.32% 16:43 07/13 EDT
OPEN
47.92
PREV CLOSE
46.89
HIGH
56.93
LOW
47.92
VOLUME
1.34M
TURNOVER
--
52 WEEK HIGH
62.97
52 WEEK LOW
8.49
MARKET CAP
1.03B
P/E (TTM)
-21.0865
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ARCT stock price target is 51.00 with a high estimate of 69.00 and a low estimate of 18.00.

EPS

ARCT News

More
Moderna completes enrollment in mid-stage study of COVID-19 vaccine
In a post on social media, Moderna (MRNA +2.0%) announces that it has completed enrollment in a Phase 2 clinical trial evaluating the safety, reactogenicit
seekingalpha · 5d ago
Arcturus Therapeutics Holdings Inc. (ARCT): Hedge Funds Sticking Around
Insider Monkey · 07/05 19:25
Is This Under-the-Radar Stock a Better Coronavirus Play Than Moderna?
MotleyFool.com · 07/05 13:07
Smaller cap COVID-19 vaccine players under pressure on Pfizer data
Seeking Alpha - Article · 07/01 15:32
Arcturus Therapeutics Announces the Formation of its Vaccine Platform Scientific Advisory Board
GlobeNewswire · 07/01 13:00
Arcturus Therapeutics Announces Formation Of Its Vaccine Platform Scientific Advisory Board
Renowned experts in virology, infectious disease, vaccine development and public health to support Arcturus' COVID-19 vaccine program, LUNAR-COV19   Company remains on track to begin clinical trial for COVID-19
Benzinga · 07/01 12:06
FDA guides on COVID-19 vaccine approval criteria
Seeking Alpha - Article · 06/30 16:01
Arcturus Therapeutics to be Added to Russell 2000® Index
GlobeNewswire · 06/29 13:00

Industry

Biotechnology & Medical Research
-1.49%
Pharmaceuticals & Medical Research
+0.02%

Hot Stocks

Symbol
Price
%Change

About ARCT

Arcturus Therapeutics Holdings Inc. is a ribonucleic acid (RNA) medicines company focused on liver and respiratory diseases. In addition to its internal messenger RNA (mRNA) platform, its lipid nanoparticle deliver system, LUNAR, enables multiple nucleic acid medicines. It is expertized in the discovery and development of RNA medicines, including in the production of RNA drug substance and nanoparticle-formulated drug product. It has a pipeline of seven drugs in the late-stage discovery and early-stage development out of which two are wholly-owned and five are pharma partnered programs. It is focused on applying its technologies to develop RNA medicines in multiple therapeutic approaches, which include mRNA, deoxyribonucleic acid (DNA), and replicon protein replacement for therapeutics and protein delivery for vaccines; small interfering RNA (siRNA), microRNA, and antisense oligonucleotides knockdown of genes overexpressed in disease; and CRISPR, TALEN and zinc finger proteins.
More

Webull offers kinds of Arcturus Therapeutics Holdings Inc stock information, including NASDAQ:ARCT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARCT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ARCT stock methods without spending real money on the virtual paper trading platform.